Brief: Tcr² Therapeutics Reports Third Quarter 2021 Financial Results
TCR2 Therapeutics Inc expected to post a loss of 65 cents a share - Earnings Preview
Brief: TCR² Therapeutics Reports Expansion of U.S. Manufacturing Capacity
Brief: TCR2 Therapeutics Says Ceasing Manufacturing Operations At Facility In Stevenage, UK
U.S. STOCKS ON THE MOVE-Remark Holdings, Erytech Pharma, Pinterest, Bakkt Holdings
U.S. STOCKS ON THE MOVE-Pinterest, Tesla, Erytech Pharma, Remark
U.S. STOCKS ON THE MOVE-Remark Holdings, PAE, Tesla, Xeris
TCR2 Therapeutics up on clinical trial collaboration with Bristol Myers
Brief: TCR Therapeutics Announces Clinical Trial Collaboration Agreement With Bristol Myers Squibb
Brief: TCR2 Therapeutics Inc - Gavo-Cel Recommended Phase 2 Dose (Rp2d) Identification Before Year-End
Brief: Tcr² Therapeutics Presents Preclinical Data On Il-15 Enhanced Trucs At Aacr Virtual Special Conference On Tumor Immunology & Immunotherapy
Brief: H.C.Wainwright Cuts PT On TCR2 Therapeutics To $25 From $37
U.S. RESEARCH ROUNDUP- BorgWarner, Doma Holdings, Visteon
U.S. STOCKS ON THE MOVE-CuriosityStream, Innate Pharma, Helbiz
U.S. STOCKS ON THE MOVE-Protagonist Therapeutics, ForgeRock, Beigene
U.S. STOCKS ON THE MOVE-Corvus Pharma, Take-Two, Silverback Therapeutics
Brief: TCR² Therapeutics Reports Positive Interim Results from Ongoing Trial of Gavo-cel
Brief: TCR2 Therapeutics To Announce Results From Ongoing Phase 1/2 Trial Of Gavo-Cel In Mesothelin-Expressing Solid Tumors
Brief: TCR2 Therapeutics Gets FDA Orphan Drug Designation For Cholangiocarcinoma Treatment